---
title: 'CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma:
  towards a rational approach'
date: '2023-11-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38030311/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231130170657&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: The approval of CD19-directed chimeric antigen receptor (CAR) T-cell
  therapies for the second-line treatment of high-risk large B-cell lymphoma (LBCL)
  has greatly affected salvage algorithms for this condition, and such therapies could
  have the potential to improve the course of relapsed or refractory LBCL. In this
  Review, we provide guidance for a rational management approach to the use of commercial
  CD19-directed CAR T cells in the second-line treatment of LBCL, addressing crucial
  ...
disable_comments: true
---
The approval of CD19-directed chimeric antigen receptor (CAR) T-cell therapies for the second-line treatment of high-risk large B-cell lymphoma (LBCL) has greatly affected salvage algorithms for this condition, and such therapies could have the potential to improve the course of relapsed or refractory LBCL. In this Review, we provide guidance for a rational management approach to the use of commercial CD19-directed CAR T cells in the second-line treatment of LBCL, addressing crucial ...